Clusterin (CLU) is a molecular chaperone that participates in a variety of biological processes. Recent studies indicate its possible involvement in the development of bone erosions and autoimmunity. The aim of this study was to investigate its serum concentrations in patients with early rheumatoid arthritis (RA) and to explore their potential relationship with disease activity and treatment response. Serum levels of CLU were measured in 52 patients before and 3 months after the initiation of treatment and in 52 healthy individuals. CLU levels at baseline were significantly increased in patients with early RA compared with healthy subjects (p < 0.0001). After 3 months of treatment, the levels of CLU decreased and reached concentrations comparable to those in controls. Even though there was no relationship between CLU levels and disease activity at baseline, CLU levels positively correlated with disease activity at months 3, 6 and 12 after treatment initiation. Using ROC analysis, lower CLU baseline levels predicted achieving the therapeutic target of low disease activity and remission at months 3, 6 and 12. In summary, we found increased serum concentrations of clusterin in treatment-naïve patients with early rheumatoid arthritis, and we suggest clusterin as a predictive biomarker of disease activity and treatment response.

Department of Rheumatology 1st Faculty of Medicine Charles University Prague Czech Republic

Faculty of Science Charles University Prague Czech Republic

Institute of Rheumatology Na Slupi 4 128 00 Prague 2 Czech Republic

Zobrazit více v PubMed

Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388:2023–2038. doi: 10.1016/S0140-6736(16)30173-8. PubMed DOI

Firestein GS, McInnes IB. Immunopathogenesis of rheumatoid arthritis. Immunity. 2017;46:183–196. doi: 10.1016/j.immuni.2017.02.006. PubMed DOI PMC

McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389:2328–2337. doi: 10.1016/S0140-6736(17)31472-1. PubMed DOI

Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann. Rheum. Dis. 2017;76:960–977. doi: 10.1136/annrheumdis-2016-210715. PubMed DOI

Romão VC, Canhão H, Fonseca JE. Old drugs, old problems: Where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs? BMC Med. BioMed. Central. 2013;11:17. PubMed PMC

Wijbrandts CA, Tak PP. Prediction of response to targeted treatment in rheumatoid arthritis. Mayo Clin. Proc. 2017;92:1129–1143. doi: 10.1016/j.mayocp.2017.05.009. PubMed DOI

Maillefert J-F, Puéchal X, Falgarone G, Lizard G, Ornetti P, Solau E, et al. Prediction of response to disease modifying antirheumatic drugs in rheumatoid arthritis. Jt. Bone Spine. 2010;77:558–563. doi: 10.1016/j.jbspin.2010.02.018. PubMed DOI

Murphy BF, Kirszbaum L, Walker ID, D’Apice JF. Sp-40,40, a newly identified normal human serum protein found in the SC5b-9 complex of complement and in the immune deposits in glomerulonephritis. J. Clin. Invest. 1988;81:1858–1864. doi: 10.1172/JCI113531. PubMed DOI PMC

Choi-Miura NH, Takahashi Y, Nakano Y, Tobe T, Tomita M. Identification of the disulfide bonds in human plasma protein SP-40,40 (Apolipoprotein-J) J. Biochem. 1992;112:557–561. doi: 10.1093/oxfordjournals.jbchem.a123938. PubMed DOI

Aronow BJ, Lund SD, Brown TL, Harmony JA, Witte DP. Apolipoprotein J expression at fluid-tissue interfaces: Potential role in barrier cytoprotection. Proc. Natl. Acad. Sci. USA. 1993;90:725–729. doi: 10.1073/pnas.90.2.725. PubMed DOI PMC

Koltai T. Clusterin: A key player in cancer chemoresistance and its inhibition. Oncol. Targets. Ther. 2014;20:447–456. doi: 10.2147/OTT.S58622. PubMed DOI PMC

Gassler N, Autschbach F, Heuschen G, Witzgall R, Otto HF, Obermüller N. Expression of clusterin in Crohn’s disease of the terminal ileum. Histol. Histopathol. 2001;16:755–762. PubMed

Fandridis E, Apergis G, Korres DS, Nikolopoulos K, Zoubos AB, Papassideri I, et al. Increased expression levels of apolipoprotein J/clusterin during primary osteoarthritis. Vivo (Brooklyn) 2011;25:745–749. PubMed

Devauchelle V, Essabbani A, De Pinieux G, Germain S, Tourneur L, Mistou S, et al. Characterization and functional consequences of underexpression of clusterin in rheumatoid arthritis. J. Immunol. 2006;177:6471–6479. doi: 10.4049/jimmunol.177.9.6471. PubMed DOI

Humphreys DT, Carver JA, Easterbrook-Smith SB, Wilson MR. Clusterin has chaperone-like activity similar to that of small heat shock proteins. J. Biol. Chem. 1999;274:6875–6881. doi: 10.1074/jbc.274.11.6875. PubMed DOI

Schwochau GB, Nath KA, Rosenberg ME. Clusterin protects against oxidative stress in vitro through aggregative and nonaggregative properties. Kidney Int. 1998;53:1647–1653. doi: 10.1046/j.1523-1755.1998.00902.x. PubMed DOI

Trougakos IP, Lourda M, Antonelou MH, Kletsas D, Gorgoulis VG, Papassideri IS, et al. Intracellular clusterin inhibits mitochondrial apoptosis by suppressing p53-activating stress signals and stabilizing the cytosolic Ku70-Bax protein complex. Clin. Cancer Res. 2009;15:48–59. doi: 10.1158/1078-0432.CCR-08-1805. PubMed DOI PMC

Jeong S, Ledee DR, Gordon GM, Itakura T, Patel N, Martin A, et al. Interaction of clusterin and matrix metalloproteinase-9 and its implication for epithelial homeostasis and inflammation. Am. J. Pathol. 2012;180:2028–2039. doi: 10.1016/j.ajpath.2012.01.025. PubMed DOI PMC

Choi B, Kang S-S, Kang S-W, Min B-H, Lee E-J, Song D-H, et al. Secretory clusterin inhibits osteoclastogenesis by attenuating M-CSF-dependent osteoclast precursor cell proliferation. Biochem. Biophys. Res. Commun. 2014;450:105–109. doi: 10.1016/j.bbrc.2014.05.074. PubMed DOI

Kropáčková T, Šléglová O, Růžičková O, Vencovský J, Pavelka K, Šenolt L. Lower serum clusterin levels in patients with erosive hand osteoarthritis are associated with more pain. BMC Musculoskelet. Disord. 2018;19:20. doi: 10.1186/s12891-018-2179-3. PubMed DOI PMC

Cunin P, Beauvillain C, Miot C, Augusto J-F, Preisser L, Blanchard S, et al. Clusterin facilitates apoptotic cell clearance and prevents apoptotic cell-induced autoimmune responses. Cell Death Dis. 2016;7:e2215. doi: 10.1038/cddis.2016.113. PubMed DOI PMC

Falgarone G, Essabbani A, Dumont F, Cagnard N, Mistou S, Chiocchia G. Implication of clusterin in TNF-α response of rheumatoid synovitis: Lesson from in vitro knock-down of clusterin in human synovial fibroblast cells. Physiol. Genom. 2012;44:229–235. doi: 10.1152/physiolgenomics.00095.2010. PubMed DOI

Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann. Rheum. Dis. 2010;69:1580–1588. doi: 10.1136/ard.2010.138461. PubMed DOI

Fransen J, van Riel PLCM. The disease activity score and the EULAR response criteria. Rheum. Dis. Clin. N. Am. 2009;20:745–757. doi: 10.1016/j.rdc.2009.10.001. PubMed DOI

Canhão H, Rodrigues AM, Gregório MJ, Dias SS, Gomes JAM, Santos MJ, et al. Common evaluations of disease activity in rheumatoid arthritis reach discordant classifications across different populations. Front. Med. 2018;5:40. doi: 10.3389/fmed.2018.00040. PubMed DOI PMC

Aletaha D, Martinez-Avila J, Kvien TK, Smolen JS. Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index. Ann. Rheum. Dis. 2012;71:1190–1196. doi: 10.1136/annrheumdis-2012-201491. PubMed DOI

Tarquini C, Pucci S, Scioli MG, Doldo E, Agostinelli S, D’Amico F, et al. Clusterin exerts a cytoprotective and antioxidant effect in human osteoarthritic cartilage. Aging (Albany, NY) 2020;12:10129–10146. doi: 10.18632/aging.103310. PubMed DOI PMC

Connor JR, Kumar S, Sathe G, Mooney J, O’Brien SP, Mui P, et al. Clusterin expression in adult human normal and osteoarthritic articular cartilage. Osteoarthrit. Cartil. 2001;9:727–737. doi: 10.1053/joca.2001.0475. PubMed DOI

Trougakos IP, Gonos ES. Clusterin/Apolipoprotein J in human aging and cancer. Int. J. Biochem. Cell Biol. 2002;20:1430–1448. doi: 10.1016/S1357-2725(02)00041-9. PubMed DOI

Trougakos IP, Poulakou M, Stathatos M, Chalikia A, Melidonis A, Gonos ES. Serum levels of the senescence biomarker clusterin/apolipoprotein J increase significantly in diabetes type II and during development of coronary heart disease or at myocardial infarction. Exp. Gerontol. 2002;20:1175–1187. doi: 10.1016/S0531-5565(02)00139-0. PubMed DOI

Crowson CS, Liao KP, Davis JM, Solomon DH, Matteson EL, Knutson KL, et al. Rheumatoid arthritis and cardiovascular disease. Am. Heart J. 2013;20:622. doi: 10.1016/j.ahj.2013.07.010. PubMed DOI PMC

Turkieh A, Porouchani S, Beseme O, Chwastyniak M, Amouyel P, Lamblin N, et al. Increased clusterin levels after myocardial infarction is due to a defect in protein degradation systems activity. Cell Death Dis. 2019;10:608. doi: 10.1038/s41419-019-1857-x. PubMed DOI PMC

Ha J, Moon MK, Kim H, Park M, Cho So Y, Lee J, et al. Plasma clusterin as a potential link between diabetes and Alzheimer disease. J. Clin. Endocrinol. 2020;105:3058–3068. doi: 10.1210/clinem/dgaa378. PubMed DOI

Baralla A, Sotgiu E, Deiana M, Pasella S, Pinna S, Mannu A, et al. Plasma Clusterin and lipid profile: A link with aging and cardiovascular diseases in a population with a consistent number of centenarians. PLoS One. 2015;10:128029. PubMed PMC

Jones SE, Jomary C. Clusterin. Int. J. Biochem. Cell Biol. 2002;34:427–431. doi: 10.1016/S1357-2725(01)00155-8. PubMed DOI

Leskov KS, Klokov DY, Li J, Kinsella TJ, Boothman DA. Synthesis and functional analyses of nuclear clusterin, a cell death protein. J. Biol. Chem. 2003;278:11590–11600. doi: 10.1074/jbc.M209233200. PubMed DOI

Prochnow H, Gollan R, Rohne P, Hassemer M, Koch-Brandt C, Baiersdörfer M. Non-secreted clusterin isoforms are translated in rare amounts from distinct human mRNA variants and do not affect Bax-mediated apoptosis or the NF-κB signaling pathway. PLoS One. 2013;8:e75303. doi: 10.1371/journal.pone.0075303. PubMed DOI PMC

Smith MD, Kraan MC, Slavotinek J, Au V, Weedon H, Parker A, et al. Treatment-induced remission in rheumatoid arthritis patients is characterized by a reduction in macrophage content of synovial biopsies. Rheumatology. 2001;40:367–374. doi: 10.1093/rheumatology/40.4.367. PubMed DOI

Gerlag DM, Haringman JJ, Smeets TJM, Zwinderman AH, Kraan MC, Laud PJ, et al. Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis. Arthritis Rheum. 2004;50:3783–3791. doi: 10.1002/art.20664. PubMed DOI

The therapeutic and prognostic role of clusterin in diverse musculoskeletal diseases: a mini review